Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers

Autor(es)

de Oliveira, Isabela Fernandes ^[1] ; Barbosa, Eduardo Jose ^[1] ; Camasmie Peters, Maria Christina ^[1] ; Bazan Henostroza, Mirla Anali ^[1] ; Yukuyama, Megumi Nishitani ^[1] ; Neto, Edson dos Santos ^[2] ; Lobenberg, Raimar ^[3] ; Bou-Chacra, Nadia ^[1]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Pharmaceut Sci, Dept Pharm, Ave Prof Lineu Prestes 508, BR-05508900 Sao Paulo, SP - Brazil

^[2] Univ Sao Paulo, Clin Hosp, Ophthalmol Div, Fac Med, Ave Dr Eneas de Carvalho Aguiar 255, BR-05403000 Sao Paulo, SP - Brazil

^[3] Univ Alberta, Fac Pharm & Pharmaceut Sci, Katz Grp Rexall Ctr Pharm & Hlth Res, Div Pharmaceut Sci, 11361-87 Ave, Room 3-142-K, Edmonton, AB T6G 2E1 - Canada

• Tipo de documento: Artigo de Revisão
• Fonte: International Journal of Pharmaceutics; v. 589, NOV 15 2020.
• Citações Web of Science: 0

Resumo

Posterior segment eye diseases affect more than 300 million patients worldwide resulting in severe visual impairment. The treatments available are invasive, costly, present irregular effectiveness, and cause serious adverse effects. These drawbacks significantly reduce patient compliance. In the last decade, solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) have shown potential as innovative carriers for lipophilic drug substances to overcome hurdles in treating the eye posterior segment. This review shows the advantages of these formulations, focusing on their compatibility with ocular tissues, which increases the internalization of the drug substances. Additionally, SLN and NLC can reduce the clearance by the eye's protective mechanisms due to adhesive properties related to nanometric size. Therefore, these preparations may allow the treating of several ophthalmic diseases by topical administration, increasing the interval between doses. This feature can decrease adverse effects and enhance efficacy, ultimately improving patient compliance. Thus, this critical review presents the performance of the in vitro, ex vivo, and in vivo assays that support the potential of SLN and NLC to treat diseases of the posterior segment of the eye. These nanoparticles have shown to be promising alternative towards a major shift in developing ophthalmic products. (AU)

• Processo FAPESP: 18/24529-4 - Nanocristais de Lapdesf GL-FT 5 para o tratamento do edema macular diabético: preparação e caracterização físico-química
• Beneficiário: Isabela Fernandes de Oliveira
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica